Objective: The liver plays a major role in the metabolism and elimination of many antiepileptic drugs (AEDs), including perampanel. Some of the metabolites identified for perampanel are likely formed via reactive intermediates, which have the potential to covalently bind to protein and cause idiosyncratic toxicities, including hepatotoxicity. The approved AED perampanel is a selective, noncompetitive AMPA receptor antagonist. The safety and tolerability of perampanel have been well documented in 3 double-blind, randomized, placebo-controlled, phase III studies. Here we report the effects of perampanel on liver function in patients from the phase III studies to assess the potential for liver toxicity. Methods: Following 6-week baseline, patients (≥12 years old) with drug-resistant partial seizures were randomized to once-daily double-blind treatment (6-week titration, 13-week maintenance) with 2, 4, 8, or 12 mg perampanel (n = 1038) or with placebo (n = 442). Clinical laboratory tests for hepatobiliary laboratory parameters were evaluated at baseline and at end of treatment. These included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma-glutamyl transpeptidase, and total bilirubin. Treatment-emergent markedly abnormal values (an increase in NCI-CTC grade relative to baseline and a grade ≥2) and treatment-emergent adverse events (TEAEs) related to hepatobiliary parameters were also recorded.
Introduction
Approximately 2.2 million Americans are currently diagnosed with epilepsy, a chronic disease of the brain in which patients can have at least 2 unprovoked seizures occurring >24 h apart; 1 unprovoked seizure and a probability of further seizures similar to the general recurrence risk (≥60%) after two unprovoked seizures, occurring over the next 10 years; or a diagnosis of an epilepsy syndrome (Fisher et al., 2014 ; Institute of Medicine of the National Academies et al., 2012) . Abnormal excessive or synchronous neuronal activity in the brain results in an epileptic seizure (Fisher et al., 2005) . Initial treatment of epilepsy requires the therapeutic use of antiepileptic drugs (AEDs) in order to control seizures, avoid drug-induced adverse events, and maintain quality of life (Elger and Schmidt, 2008) .
Many drugs, including AEDs, are metabolized and eliminated by the liver (Ahmed and Siddiqi, 2006; Hussein et al., 2013; Lee, 1995) , and thus there is the potential for drug-induced liver injury/toxicity (Hussein et al., 2013) . For some AEDs, such as valproic acid and felbamate, a risk of hepatotoxicity is evident and linked to the formation of reactive metabolic intermediates (Zaccara et al., 2007) . Reactive intermediates have the potential of covalently binding to proteins, especially if reduced glutathione (GSH) levels become depleted, thus impairing detoxification (Ballet, 2010; Begriche et al., 2011; Evans et al., 2004; Lammert et al., 2010) . This mechanism is considered to play a role in causing idiosyncratic toxicities, including hepatotoxicity (Ballet, 2010; Evans et al., 2004; Lammert et al., 2010) . However, there is also evidence of a clinical daily dose threshold below 10 mg/day for which idiosyncratic toxicities are rare (Ballet, 2010; Evans et al., 2004; Nakayama et al., 2009; Uetrecht, 2001) . Additionally, the metabolite of the parent drug and/or the products of oxidation can cause injury to hepatic cell components as well as the bile ducts, causing cholestasis (Lee, 1995) . A number of blood tests measuring liver enzyme levels can assist in determining the health of the liver (Pratt and Kaplan, 2000) . Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) can serve as markers of hepatocellular injury, while alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) can indicate an obstruction in the bile ducts, cholestasis, or hepatobiliary disease (Hussein et al., 2013; Pratt and Kaplan, 2000) . A few AEDs are associated with drug-induced liver toxicity and require regular monitoring of liver enzymes or discontinuation of the drug (Hussein et al., 2013; Warner et al., 1998) .
Perampanel is a first-in-class, orally active, noncompetitive, selective AMPA glutamate receptor antagonist approved in more than 40 countries, including the United States and in the European Union, for adjunctive treatment of partial seizures with or without secondarily generalized seizures, in patients with epilepsy aged ≥12 years (in Canada, perampanel is approved in patients aged ≥18 years) (FYCOMPA SPC, 2012; FYCOMPA Product Monograph, 2013; FYCOMPA Prescribing Information, 2014; Hanada et al., 2011; Krauss et al., 2013) . The efficacy and safety of perampanel in patients with treatment-resistant partial seizures have been demonstrated in three multicenter, double-blind (DB), randomized, parallel-group, placebocontrolled, phase III studies (French et al., , 2013 Krauss et al., 2012) . Similar to other AEDs that are metabolized predominantly by the liver (Ahmed and Siddiqi, 2006) , perampanel is extensively metabolized via CYP3A4 and CYP3A5 enzymes, with the main pathway being oxidation and subsequent glucuronidation (Rektor, 2013; Rogawski and Hanada, 2013) . The potential for perampanel to result in liver toxicity was intensively assessed clinically using the data from the three Phase III studies. Here we report the comprehensive evaluation of perampanel on liver function tests undertaken to assess the potential for liver toxicity.
Methods
The three phase III studies (study 304: NCT00699972; 305: NCT00699582; 306: NCT00700310) were conducted between April 2008 and January 2011 (French et al., , 2013 Krauss et al., 2012) . All studies were compliant with the Helsinki Declaration, the European Medicines Agency requirements, and the US Code of Federal Regulations, as appropriate. Study protocols, amendments, and informed consents were reviewed by national regulatory authorities in each country and by independent ethics committees or institutional review boards for each site. All patients provided written informed consent before participation.
The three phase III core studies were randomized, double-blind, placebo-controlled evaluations of adjunctive perampanel at doses of 2 mg/day to 12 mg/day. Following a 6-week baseline period, patients were randomized to once-daily, double-blind, 19-week treatment (6-week titration, 13-week maintenance) with placebo or perampanel 8 or 12 mg (Studies 304 and 305) or with placebo or perampanel 2, 4, or 8 mg (Study 306) (Fig. 1 ). Patients included in these studies were aged ≥12 years with drug-resistant partial seizures and were receiving 1-3 concomitant AEDs. The detailed inclusion and exclusion criteria for all three studies have been published previously (French et al., , 2013 Krauss et al., 2012) . During the 6-week titration period, perampanel doses were increased by 2 mg/day/week until the randomized dose or intolerability was reached (French et al., , 2013 Krauss et al., 2012) . During the 13-week treatment period, patients continued on the dose achieved during titration. Patients also continued receiving their established concomitant AEDs without modification.
Blood samples were taken at screening; baseline; weeks 6, 10, 14, 19, and 23; and discontinuation. Clinical laboratory tests for hepatobiliary laboratory parameters were evaluated at baseline and at the end of treatment for the following: alkaline phosphatase (ALP); alanine aminotransferase (ALT); aspartate aminotransferase (AST); gamma-glutamyl transpeptidase (GGT); and total bilirubin.
Hepatobiliary laboratory data were summarized through descriptive statistics and shift tables relative to laboratory normal range. Treatment-emergent markedly abnormal values, defined as laboratory results that worsened in severity relative to baseline, to meet modified National Cancer Institute Common Toxicity Criteria (NCI-CTC) of ≥grade 2, were also captured.
Based on liver function tests, additional analyses were performed. For ALP, ALT, AST, and GGT, the number of patients with values that were ≤3× the upper limit of normal (ULN), >3× ULN but ≤5× ULN, and >5× ULN was calculated; and for total bilirubin, the number of patients with values ≤2× ULN and >2× ULN was calculated. Treatmentemergent adverse events (TEAEs) related to hepatobiliary parameters were also recorded.
Results

Mean hepatobiliary laboratory values
The safety population of the phase III pooled studies included 1038 patients treated with perampanel (2 mg, n = 180; 4 mg, n = 172; 8 mg, n = 431; 12 mg, n = 255) and 442 patients treated with placebo. Fig. 2 shows mean values for hepatobiliary laboratory parameters taken at baseline and at the end of treatment in patients in the placebo and perampanel treatment groups. Mean values of ALP, ALT, AST, GGT, and total bilirubin were within normal ranges at baseline and end of treatment for all perampanel dose groups and placebo. Mean changes from baseline to end of treatment were small and not meaningful.
Shift from baseline to end of treatment in hepatobiliary laboratory values
Shifts in values from baseline to end of treatment for hepatobiliary laboratory parameters, relative to normal ranges, were not of clinical concern (Table 1 ). The majority of hepatobiliary parameters for perampanel and placebo were normal at baseline and remained normal at end of treatment. The percent of patients treated with perampanel that had hepatobiliary parameters values within the normal range at the end of treatment was similar to placebo-treated patients (Table 1) .
Treatment-emergent markedly abnormal hepatobiliary parameters
As shown in Table 2 , treatment-emergent markedly abnormal results (an increase in NCI-CTC grade relative to baseline and a grade ≥2) occurred in ≤3.1% of patients in any treatment group. The incidence of markedly abnormal results was very low for perampanel-and placebo-treated patients, and no dose-related trends were observed. 
Laboratory values of special interest--Additional liver function tests
Hepatobiliary laboratory values of special interest are shown in Table 3 . For ALP, ALT, and AST, there were no patients from any treatment group who had values >5× ULN. Values that were >3× ULN but ≤5× ULN occurred in similarly low percentages in patients treated with perampanel (0.5%, 0.3%, 0.1% for AST, ALT, and ALP, respectively) and those treated with placebo (0.2%, 0.2%, 0% for AST, ALT, and ALP, respectively). There were no dose-related trends across the perampanel groups. For GGT, values >5× ULN were observed in 1.8% (n = 18) and 2.1% (n = 9) of all perampaneltreated and placebo-treated patients, respectively. GGT values that were >3× ULN but ≤5× ULN occurred at similar rates in the total perampanel group (4.0%, n = 41) and the placebo group (3.5%, n = 15), and showed no doserelated trends. For the parameter of total bilirubin, 1 (0.1%) perampanel-treated patient had a value >2× ULN. This patient, randomized to the 2 mg/day perampanel group, was a 24-year-old female with a history of hepatitis who had bilirubin values of 39 mol/L at baseline and 34-48 mol/L at all post-baseline evaluations, all of which were above normal range (3-21 mol/L). Her values for ALP, ALT, and AST were within, or slightly below, the normal ranges at each evaluation. This patient had no adverse events during the study.
No patient had values that met the criteria for Hy's Law (i.e., AST or ALT >3× ULN, total bilirubin >2× ULN, and ALP <2× ULN) (Table 3 and Fig. 3 ). In Fig. 3 , the Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) (Watkins et al., 2011) approach shows that 1 (0.2%) patient receiving placebo and 3 (0.3%) patients receiving perampanel met the criteria for Temple's Corollary (ALT >3× ULN but not satisfying Hy's Law). Further analysis of these 4 subjects showed that hepatobiliary laboratory test values did not increase with perampanel treatment during the course of the study and the reported abnormalities appear to be isolated findings (Fig. 4) . These subjects completed the double-blind study and continued with the open-label extension study, with no patient meeting Hy's Law or Temple's Corollary criteria during the extension.
TEAEs related to hepatobiliary parameters
TEAEs related to hepatobiliary parameters occurred in 0.4% (n = 4) of total perampanel-treated patients and 0% (n = 0) of placebo-treated patients. These TEAEs included cholelithiasis, which occurred in perampanel patients receiving 4 mg (0.6%, n = 1), 8 mg (0.2%, n = 1), and 12 mg (0.4%, n = 1); and abnormal hepatic function, which occurred in 1 perampanel patient treated with 4 mg (0.6%). None of the events was serious, and none led to discontinuation of perampanel. The patient with abnormal hepatic function was one of the patients who met the criteria for Temple's Corollary.
Subgroup analysis of hepatobiliary data by baseline concomitant AED
To determine whether concomitant AEDs had an effect on any hepatobiliary parameters, a subgroup analysis was performed. In this analysis, concomitant AEDs included carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and valproic acid. Patients taking carbamazepine, lamotrigine, topiramate, and valproic acid were recorded to have TEAEs related to hepatobiliary parameters (cholelithiasis or abnormal hepatic function). However, no meaningful differences with any specific AED were observed. Treatment-emergent markedly abnormal laboratory results (i.e., an increase in NCI-CTC grade relative to baseline and a grade ≥2) for hepatobiliary parameters by concomitant AEDs were also examined. In this subanalysis, the incidence of treatment-emergent markedly abnormal laboratory results for AST, ALT, ALP, and total bilirubin was less than 1% for the concomitant AEDs in the placebo and total perampanel groups. Treatment-emergent markedly abnormal laboratory values for ALT and total bilirubin were reported in perampanel-treated patients taking concomitant carbamazepine (n = 2, 0.6%; n = 1, 0.3%; respectively) and valproic acid (n = 2, 0.6%; n = 2, 0.6%; respectively); for AST in patients taking lamotrigine (n = 2, 0.6%), levetiracetam (n = 2, 0.7%), oxcarbazepine (n = 1, 0.6%), topiramate (n = 1, 0.5%), and valproic acid (n = 3, 0.9%); and in no patient for ALP. For GGT, the incidence of treatment-emergent markedly abnormal laboratory values was similar between patients treated with perampanel (range: 1.5-3.2%) and those treated with placebo (range: 1.6-3.6%) for all concomitant AEDs. Taken together, treatment-emergent markedly abnormal laboratory values showed no meaningful differences with any specific AED.
Discussion
The liver plays a major role in the metabolism of a majority of drugs, including AEDs (Ahmed and Siddiqi, 2006; Hussein et al., 2013; Lee, 1995) . Hepatotoxicity is rare, and can be a result of metabolites or toxic by-products that can disrupt the integrity of the hepatocyte structure and function (Ahmed and Siddiqi, 2006; Lee, 1995) . Because the liver is the primary elimination route for many AEDs and administration of some of these AEDs has resulted in elevated liver enzymes (markers of hepatocellular injury), it is important to assess and understand the potential for liver toxicity with new AEDs (Ahmed and Siddiqi, 2006; Lee, 1995; Warner et al., 1998) . Although the mild elevations of liver enzymes can be transitory, monitoring of hepatic function is recommended for some AEDs (Ahmed and Siddiqi, 2006; Warner et al., 1998) . When liver enzyme levels increase to >3× ULN, there is a potential for liver disease and clinicians may consider dose reduction of the AED or discontinuation and switching to a different AED (Ahmed and Siddiqi, 2006; Warner et al., 1998 ).
Here we demonstrate that the first-in-class AED perampanel has no clinically important effects on liver function tests, indicating low potential for liver toxicity. Perampanel, an adjunctive treatment for partial seizures, is extensively metabolized via primary oxidation (mainly by CYP3A4 and CYP3A5) and sequential glucuronidation (FYCOMPA Prescribing Information, 2014; Rektor, 2013; Rogawski and Hanada, 2013) . Some of the metabolites identified for perampanel appear likely to be formed via reactive intermediates (Rheims and Ryvlin, 2013) . Idiosyncratic toxicities, including hepatotoxicity, have been associated with the mechanism in which reactive intermediates covalently bind to proteins, especially if reduced glutathione (GSH) levels have become depleted (Ballet, 2010; Begriche et al., 2011; Lammert et al., 2010) . Covalent binding has been observed in preclinical studies of perampanel, at exposures much higher than clinical exposures. Importantly, there is evidence that idiosyncratic toxicities are rare when the clinical daily dose of drug is given at daily doses ≤10 mg (Ballet, 2010; Evans et al., 2004; Nakayama et al., 2009; Uetrecht, 2001) . The daily clinical dose for perampanel is 4-12 mg/day, which compares favorably relative to the much higher doses of other AEDs known to cause idiosyncratic toxicities (Nakayama et al., 2009) , providing further support for perampanel's low potential of hepatotoxicity. Laboratory tests measuring liver enzyme levels revealed that the mean values of ALP, ALT, AST, GGT, and total bilirubin were within normal ranges at baseline and at end of treatment in patients taking all therapeutic doses of perampanel (4-12 mg). Markedly abnormal results for liver enzymes were very infrequent in perampanel-treated patients and no dose-related trends in abnormal results were observed, suggesting normal liver function. No serious adverse events related to the liver were observed, and no perampanel-treated patients discontinued due to TEAEs related to hepatobiliary parameters.
Although some patients had liver enzymes >3× ULN, the percentages were low and were similar for perampaneland placebo-treated patients. There were no reports of patients from the phase III perampanel clinical studies meeting the criteria for Hy's Law. A predictor of a drug's potential to induce liver toxicity is the occurrence of hepatocellular injury (indicated by aminotransferase elevation) accompanied by increased serum total bilirubin, not explained by any other cause and without evidence of cholestasis, compared to placebo/control (US Food and Drug Administration Guidance for Industry, 2009). The evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) is a tool that graphically displays peak serum ALT and total bilirubin levels obtained from laboratory data for each subject (Watkins et al., 2011) . Here we present a similar graphic (Fig. 3) for the patients in the 3 phase III perampanel studies. Temple's Corollary (ALT >3× ULN but not satisfying Hy's Law) (Watkins et al., 2011) was reported in both perampanel (n = 3, 0.3%) and placebo (n = 1, 0.2%) patients. Over the course of perampanel treatment, hepatobiliary laboratory test values did not increase, suggesting that in these patients the reported abnormalities appear to be isolated findings. These results further highlight the low potential for liver toxicity with perampanel.
Routine monitoring of liver enzymes has not been indicated for perampanel, and for patients who have discontinued other AEDs due to elevations in liver enzymes, a switch to an alternative AED (Ahmed and Siddiqi, 2006) , such as perampanel, may be considered. However, the concomitant AEDs taken when patients are on polytherapy to control seizures need to be evaluated to ensure that they do not have the potential to cause liver toxicity. Some AEDs have led to the elevation of ALP, ALT, AST, and GGT (Ahmed and Siddiqi, 2006) . We have demonstrated through an analysis of hepatobiliary parameters stratified by AED taken with perampanel that concomitant use with carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and valproic acid did not yield any meaningful changes in hepatobiliary parameters.
Hepatic impairment can affect the pharmacokinetics of a drug (Verbeeck, 2008) . Based on PK data in patients with A B D C
Fig. 4 Hepatobiliary laboratory test values in patients meeting
Temple's Corollary criteria. * An unscheduled visit occurred at day 7 post baseline. ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BILI = total bilirubin; GGT = gamma-glutamyl transpeptidase; PBO = placebo; PER = perampanel; ULN = upper limit of normal. hepatic impairment, dosage adjustments are recommended for perampanel in patients with mild to moderate hepatic impairment.
(FYCOMPA Prescribing Information, 2014), which is consistent with recommendations for drugs metabolized by the liver (Verbeeck, 2008) . The following maximum daily doses are recommended due to the higher exposure and the longer half-life of perampanel in patients with mild and moderate hepatic impairment: 6 mg once daily at bedtime for patients with mild hepatic impairment and 4 mg once daily at bedtime for patients with moderate hepatic impairment, with dosage increases no more frequently than every 2 weeks (FYCOMPA Prescribing Information, 2014).
Conclusion
Perampanel did not demonstrate clinically important effects on liver function tests at any doses (2-12 mg/day).
Hepatobiliary laboratory data and related TEAEs were not notably different between the perampanel and placebo treatment groups from the 3 Phase III clinical studies, and no dose-related trends were observed. TEAEs related to hepatobiliary parameters were not considered serious and did not lead to perampanel discontinuation. Although perampanel is extensively metabolized via primary oxidation (mainly by CYP3A4 and CYP3A5) and sequential glucuronidation, (FYCOMPA Prescribing Information, 2014; Rektor, 2013; Rogawski and Hanada, 2013) , the data based on clinical laboratory tests suggest that patients treated with perampanel have a low potential for liver toxicity.
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